Financials Thalys Medical Technology Group Corporation

Equities

603716

CNE1000030C3

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 23:00:00 09/05/2024 BST 5-day change 1st Jan Change
7.98 CNY +1.66% Intraday chart for Thalys Medical Technology Group Corporation +10.22% -28.04%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 3,904 3,465 3,265 2,800 2,115 2,126
Enterprise Value (EV) 1 3,889 3,836 4,001 3,914 3,126 2,897
P/E ratio 38.8 x 30.2 x 56.8 x -57 x -13.9 x -13.5 x
Yield - 0.47% - - - -
Capitalization / Revenue 2.96 x 1.89 x 1.54 x 1.08 x 0.92 x 1.06 x
EV / Revenue 2.95 x 2.1 x 1.88 x 1.51 x 1.35 x 1.44 x
EV / EBITDA 16 x 13.1 x 16.1 x 23.8 x 74.1 x 93.7 x
EV / FCF -14.9 x -26.8 x -13.2 x -20.9 x 13 x 7.5 x
FCF Yield -6.7% -3.74% -7.6% -4.77% 7.71% 13.3%
Price to Book 2.57 x 2.25 x 1.98 x 1.81 x 1.52 x 1.76 x
Nbr of stocks (in thousands) 205,144 205,144 198,224 194,602 191,621 191,725
Reference price 2 19.03 16.89 16.47 14.39 11.04 11.09
Announcement Date 25/04/19 29/04/20 29/04/21 25/04/22 26/04/23 26/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,317 1,831 2,125 2,600 2,309 2,006
EBITDA 1 242.8 292.7 248.5 164.6 42.19 30.91
EBIT 1 184.3 227.9 174.3 94.81 -15.51 -18.91
Operating Margin 13.99% 12.45% 8.2% 3.65% -0.67% -0.94%
Earnings before Tax (EBT) 1 156.4 186.2 108.1 -24.11 -191.7 -192.5
Net income 1 94.16 110.4 57.56 -49.51 -154.4 -158.6
Net margin 7.15% 6.03% 2.71% -1.9% -6.69% -7.9%
EPS 2 0.4900 0.5600 0.2900 -0.2524 -0.7940 -0.8200
Free Cash Flow 1 -260.6 -143.4 -304.2 -186.9 240.9 386.3
FCF margin -19.78% -7.83% -14.31% -7.19% 10.44% 19.26%
FCF Conversion (EBITDA) - - - - 571.07% 1,249.88%
FCF Conversion (Net income) - - - - - -
Dividend per Share - 0.0800 - - - -
Announcement Date 25/04/19 29/04/20 29/04/21 25/04/22 26/04/23 26/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 371 737 1,114 1,011 771
Net Cash position 1 14.9 - - - - -
Leverage (Debt/EBITDA) - 1.269 x 2.965 x 6.767 x 23.95 x 24.95 x
Free Cash Flow 1 -261 -143 -304 -187 241 386
ROE (net income / shareholders' equity) 8.86% 8.77% 4.79% -2.16% -11.8% -11.2%
ROA (Net income/ Total Assets) 5.55% 5.1% 3.15% 1.45% -0.24% -0.32%
Assets 1 1,697 2,166 1,826 -3,425 65,654 48,972
Book Value Per Share 2 7.410 7.510 8.310 7.960 7.260 6.320
Cash Flow per Share 2 3.430 2.560 3.340 2.410 2.040 1.450
Capex 1 119 96.5 128 60.2 54.6 40.8
Capex / Sales 9% 5.27% 6.01% 2.32% 2.37% 2.04%
Announcement Date 25/04/19 29/04/20 29/04/21 25/04/22 26/04/23 26/04/24
1CNY in Million2CNY
Estimates
  1. Stock Market
  2. Equities
  3. 603716 Stock
  4. Financials Thalys Medical Technology Group Corporation